Publication | Open Access

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial

Nilotinib Versus ImatinibFirst-line TherapyGastrointestinal OncologyMedicineRandomised Phase 3GastroenterologyPathologyCancer TreatmentOncologyRadiation Oncology